Pharma BD Deal Intelligence

Chugai Pharma Europe Ltd. / Helsinn Group

2024 · Licensing/Option · Complete

Helsinn Group, the marketing authorisation holder for AKYNZEO, and Chugai Pharma Europe signed a renewal of their Distribution and Licence Agreement for commercialization of AKYNZEO in the United Kingdom and Republic of Ireland, extending a partnership of roughly ten years. Financial terms were not disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2029 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2024 deals